Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RUBY: dostarlimab plus carboplatin-paclitaxel versus placebo plus carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer
2023-506551-23-00Phase 3Authorised
- Sponsor
- TESARO, Inc.
- Start
- Jul 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial of dostarlimab, niraparib, carboplatin and paclitaxel in endometrial cancer (EC) (4 arms), sponsored by TESARO, Inc. Primary endpoints: Progression-free survival and Overall survival. Planned start Jul 2024; status: authorised.
02
Drugs
dostarlimabniraparibcarboplatinpaclitaxel
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2023-506551-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506551-23-00.